A review of the evidence for the use of topical antimicrobial agents in wound care

World Wide Wounds

Volumn 2004, Issue , 2004, Pages

  Cooper, Rose ^a  

^a CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Antibiotic; Antimicrobial agents; Iodine; Resistance; Silver; Wound healing

Indexed keywords

ANTIINFECTIVE AGENT; CADEXOMER IODINE; CALCIUM ALGINATE; CHLORHEXIDINE; CHLORHEXIDINE ACETATE; CHLORHEXIDINE GLUCONATE; CYSTEINE; CYTOKINE; HYDROGEN PEROXIDE; METHIONINE; POTASSIUM IODIDE; POVIDONE IODINE; PROFLAVINE; SILVER NITRATE; SULFADIAZINE SILVER;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; BETA HEMOLYTIC STREPTOCOCCUS; BIOLOGICAL THERAPY; BURN; DECUBITUS; DIABETIC FOOT; DRUG MECHANISM; DRUG PROTEIN BINDING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HONEY; HUMAN; LEG ULCER; NONHUMAN; PAIN; PATIENT CARE; PSEUDOMONAS; REVIEW; SKIN DISCOLORATION; SKIN IRRITATION; STAPHYLOCOCCUS; SURGICAL WOUND; TREATMENT PLANNING; WOUND CARE; WOUND DRESSING; WOUND HEALING; WOUND INFECTION;

EID: 4043062214     PISSN: 13692607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Forrest RD. Early history of wound treatment. J R Soc Med 1982; 75(3): 198-205.
2. Forrest RD. Development of wound therapy from the Dark Ages to the present. J R Soc Med 1982; 75(4): 268-73.
3. Mollering RC. Past, present and future of antimicrobial agents. Am J Med 1995; 99(Suppl 6A): 11S-18S.
4. Hugo WB. A brief history of heat and chemical preservation and disinfection. J Appl Bacteriol 1991; 71(1): 9-18.
5. House of Lords Select Committee for Science and Technology. Resistance to antibiotics and other antimicrobial agents, 7th report. London: HMSO, 1998.
6. Berendt T, Lipsky BA. Should antibiotics be used in the treatment of the diabetic foot? The Diabetic Foot 2003; 6(1): 19-26.
7. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14(2): 244-69.
8. Hansson C, Hoborn J, Möller A, Swanbeck G. The microbial flora in venous leg ulcers without clinical signs of infection. Repeated culture using a validated standardised microbiological technique. Acta Derm Venereol 1995; 75(1): 24-30.
9. Bowler PG, Davies BJ. The microbiology of acute and chronic wounds. Wounds 1999; 11: 72-78.
10. Trengove NJ, Stacey MC, McGechie DF, Mata S. Qualitative bacteriology and leg ulcer healing. J Wound Care 1996; 5(6): 277-80.
11. Schraibman IG. The significance of beta-haemolytic streptococci in chronic leg ulcers. Ann R Coll Surg Engl 1990; 72(2): 123-4.
12. Gilliland EL, Nathwani N, Dore CJ, Lewis JD. Bacterial colonisation of leg ulcers and its effect on the success rate of skin grafting. Ann R Coll Surg Engl 1988; 70(2): 105-8.
13. Russell AD. Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. J Appl Microbiol 2002; 92 Suppl: 121S-35S.
14. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999; 12(1): 147-79.
15. Payne DN, Babb JR, Bradley CR. An evaluation of the suitability of the European suspension test to reflect in vitro activity of antiseptics against clinically significant organisms. Lett Appl Micro 1999; 28: 7-12.
16. Cookson BD, Bolton MC, Platt JH. Chlorhexidine resistance in methicillin-resistant Staphylococcus aureus or just an elevated MIC? An in vitro and in vivo assessment. Antimicrob Agents Chemother 1991; 35(10): 1997-2002.
17. Drosou A, Falabella A, Kirsner RS. Antiseptics on wounds: an area of controversy. Wounds 2003; 15(5): 149-66.
18. Jones R. Honey and healing through the ages. In: Honey and Healing. Munn P, Jones R, editors. Cardiff: IBRA, 2001.
19. Zumla A, Lulat A. Honey - a remedy rediscovered. J R Soc Med 1989; 82(7): 384-5.
20. Molan PC. The role of honey in the management of wounds. J Wound Care 1999; 8(8): 415-8.
21. Molan PC. The antibacterial activity of honey. Part 1. Its use in modern medicine. Bee World 1992; 80(2): 5-28.
22. Cooper RA, Molan PC, Harding KG. The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds. J Appl Microbiol 2002; 93(5): 857-63.
23. Cooper RA, Halas E, Molan PC. The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns. J Burn Care Rehabil 2002; 23(6): 366-70.
24. Cooper RA, Wigley P, Burton NF. Susceptibility of multiresistant strains of Burkholderia cepacia to honey. Lett Appl Microbiol 2000; 31(1): 20-4.
25. Tonks A, Cooper RA, Price AJ, Molan PC, Jones KP. Stimulation of TNF-alpha release in monocytes by honey. Cytokine 2001; 14(4): 240-2.
26. Tonks AJ, Cooper RA, Jones KP, Blair S, Parton J, Tonks A. Honey stimulates inflammatory cytokine production from monocytes. Cytokine 2003; 21(5): 242-7.
27. Bergman A, Yanai J, Weiss J, Bell D, David MP. Acceleration of wound healing by topical application of honey. An animal model. Am J Surg 1983; 145(3): 374-6.
28. Gupta SK, Singh H, Varshney AC, Prakash P. Therapeutic efficacy of honey in infected wounds in buffaloes. Indian J Animal Sci 1992; 62(2): 521-23.
29. Oryan A, Zaker SR. Effects of topical application of honey on cutaneous wound healing in rabbits. Zentralbl Veterinarmed A 1998; 45(3): 181-8.
30. Dunford C, Cooper R, Molan P. Using honey as a dressing for infected skin lesions. Nurs Times 2000; 96(14 Suppl): 7-9.
31. Natarajan S, Williamson D, Grey J, Harding KG, Cooper RA. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatolog Treat 2001; 12(1): 33-6.
32. Cooper RA, Molan PC, Krishnamoorthy L, Harding KG. Manuka honey used to heal a recalcitrant surgical wound. Eur J Clin Microbiol Infect Dis 2001; 20(10): 758-9.
33. Moore OA, Smith LA, Campbell F, Seers K, McQuay HJ, Moore RA. Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med 2001; 1(1): 2.
34. Allen K, Molan PC, Reid GM. A survey of the antibacterial activity of some New Zealand honeys. J Pharm Pharmacol 1991; 43: 817-22.
35. Sleigh JW, Linter SP. Hazards of hydrogen peroxide. Br Med J (Clin Res Ed) 1985; 291(6510): 1706.
36. Davies J. Selections in Pathology and Surgery. Part II. London: Longman, Orme, Browne, Greene and Longmans, 1839.
37. Gottardi W. Iodine and iodine compounds. In: Disinfectants, Sterilisation and Preservations (3rd edition). Block S, editor. Philadelphia, USA: Lea Febinger, 1983.
38. Mycock G. Methicillin antiseptic-resistant Staphylococcus aureus. Lancet 1985; 2(8461): 949-50.
39. Lacey RW, Catto A. Action of povidone-iodine against methicillin-sensitive and -resistant cultures of Staphylococcus aureus. Postgrad Med J 1993; 69 Suppl 3: S78-83.
40. McLure AR, Gordon J. In-vitro evaluation of povidone-iodine and chlorhexidine against methicillin-resistant Staphylococcus aureus. J Hosp Infect 1992; 21(4): 291-9.
41. Traoré O, Fayard SF, Laveran H. An in-vitro evaluation of the activity of povidone-iodine against nosocomial bacterial strains. J Hosp Infect 1996; 34(3): 217-22.
42. Giacometti A, Cirioni O, Greganti G, Fineo A, Ghiselli R, Del Prete MS, Mocchegiani F, Fileni B, Caselli F, Petrelli E, Saba V, Scalise G. Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. Eur J Clin Microbiol Infect Dis 2002; 21(7): 553-6.
43. Lawrence JC. The use of iodine as an antiseptic agent. J Wound Care 1998; 7(8): 421-5.
44. Gilchrist B. Should iodine be reconsidered in wound management? European Tissue Repair Society. J Wound Care 1997; 6(3): 148-50.
45. Pietsch J, Meakins JL. Complications of povidone-iodine absorption in topically treated burn patients. Lancet 1976; 1(7954): 280-2.
46. Burks RI. Povidone-iodine solution in wound treatment. Phys Ther 1998; 78(2): 212-8.
47. Fumal I, Braham C, Paquet P, Piérard-Franchimont C, Piérard GE. The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study. Dermatology 2002; 204 Suppl 1: 70-4.
48. Moore K, Thomas A, Harding KG. Iodine released from the wound dressing Iodosorb modulates the secretion of cytokines by human macrophages responding to bacterial lipopolysaccharide. Int J Biochem Cell Biol 1997; 29(1): 163-71.
49. Mertz PM, Oliveira-Gandia MF, Davis SC. The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg 1999; 25(2): 89-93.
50. Danielsen L, Cherry GW, Harding K, Rollman O. Cadexomer iodine in ulcers colonised by Pseudomonas aeruginosa. J Wound Care 1997; 6(4): 169-72.
51. Zhou LH, Nahm WK, Badiavas E, Yufit T, Falanga V. Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Br J Dermatol 2002; 146(3): 365-74.
52. Mitchell GAG, Buttle GAH. Proflavine in closed wounds. Lancet 1943; ii: 749.
53. Gupta R, Foster ME, Miller E. Calcium alginate in the management of acute surgical wounds and abscesses. J Tissue Viabil 1991; 1(4): 115-16.
54. Rouch DA, Cram DS, DiBerardino D, Littlejohn TG, Skurray RA. Efflux-mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline- and sugar- transport proteins. Mol Microbiol 1990; 4(12): 2051-62.
55. Wainwright M. Acridine-a neglected antibacterial chromophore. J Antimicrob Chemother 2001; 47(1): 1-13.
56. Iwamoto Y, Ferguson LR, Pearson A, Baguley BC. Photo-enhancement of the mutagenicity of 9-anilinoacridine derivatives related to the antitumour agent amsacrine. Mutat Res 1992; 268(1): 35-41.
57. DeMarini DM, Brock KH, Doerr CL, Moore MM. Mutagenicity and clastogenicity of proflavin in L5178Y/TK +/- -3.7.2.C cells. Mutat Res 1988; 204(2): 323-8.
58. Klasen HJ. Historical review of the use of silver in the treatment of burns. I. Early uses. Burns 2000; 26(2): 117-30.
59. Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000; 26(2): 131-8.
60. Lansdown AB. Silver. I: Its antibacterial properties and mechanism of action. J Wound Care 2002; 11(4): 125-30.
61. Grier N. Silver and its compounds. In: Disinfectants, Sterilisation and Preservations (3rd edition). Block S, editor. Philadelphia, USA: Lea Febinger, 1983.
62. Trevors JT. Silver resistance and accumulation in bacteria. Enzyme Microb Technol 1987; 9: 331-33.
63. Wells TN, Scully P, Paravicini G, Proudfoot AE, Payton MA. Mechanism of irreversible inactivation of phosphomannose isomerases by silver ions and flamazine. Biochemistry 1995; 34(24): 7896-903.
64. Lansdown AB. Silver. 2: Toxicity in mammals and how its products aid wound repair. J Wound Care 2002; 11(5): 173-7.
65. Fox C. Topical therapy and the development of silver sulphadiazine. Surg Gynecol Obstet 1968; 157: 82-88.
66. Hamilton-Miller JM, Shah S, Smith C. Silver sulphadiazine: a comprehensive in vitro reassessment. Chemotherapy ; 39(6): 405-9.
67. Wlodkowski TJ, Rosenkranz HS. Antifungal activity of silver sulphadiazine. Lancet 1973; 2(7831): 739-40.
68. Speck WT, Rosenkranz HS. Letter: Activity of silver sulphadiazine against dermatophytes. Lancet 1974; 2(7885): 895-6.
69. Rahn RO, Setkiw JK, Landry LC. Ultraviolet irradiation of nucleic acids complexed with heavy metals. III Influence of Ag+ and Hg+ on the sensitivity of phage and of transforming DNA to ultraviolet radiation. Photochem Photobiol 1973; 18: 39-41.
70. Lowbury EJ, Babb JR, Bridges K, Jackson DM. Topical chemoprophylaxis with silver sulphadiazine and silver nitrate chlorhexidine creams: emergence of sulphonamide-resistant Gram-negative bacilli. Br Med J 1976; 1(6008): 493-6.
71. Heggers JP, Robson MC. The emergence of silver sulphadiazine resistance in Psuedomonas aeruginosa. Burns 1978; 5: 184-87.
72. Hendy AT, Smith IO. Silver resistant Enterobacteriaceae from hospital patients. Can J Microbiol 1979; 25: 915-21.
73. Modak SM, Fox CL. Sulfadiazine silver-resistant Pseudomonas in burns. New topical agents. Arch Surg 1981; 116(7): 854-7.
74. McManus AT, Denton CL, Mason AD. Mechanisms of in vitro sensitivity to sulfadiazine silver. Arch Surg 1983; 118(2): 161-6.
75. Pirnay JP, De Vos D, Cochez C, Bilocq F, Pirson J, Struelens M, Duinslaeger L, Cornelis P, Zizi M, Vanderkelen A. Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin Microbiol 2003; 41(3): 1192-202.
76. Gupta A, Matsui K, Lo JF, Silver S. Molecular basis for resistance to silver cations in Salmonella. Nat Med 1999; 5(2): 183-8.
77. Geronemus RG, Mertz PM, Eaglstein WH. Wound healing. The effects of topical antimicrobial agents. Arch Dermatol 1979; 115(11): 1311-4.
78. Furr JR, Russell AD, Turner TD, Andrews A. Antibacterial activity of Actisorb Plus, Actisorb and silver nitrate. J Hosp Infect 1994; 27(3): 201-8.
79. Lansdown AB, Jensen K, Jensen MQ. Contreet Foam and Contreet Hydrocolloid: an insight into two new silver-containing dressings. J Wound Care 2003; 12(6): 205-10.
80. Wright JB, Hansen DL, Burrell RE. The comparative efficacy of two antimicrobial barrier dressings: in vivo examination of two controlled release silver dressings. Wounds 1998; 10(6): 179-88.
81. Thomas S, McCubbin P. A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. J Wound Care 2003; 12(3): 101-7.
82. Thomas S, McCubbin P. An in vitro analysis of the antimicrobial properties of 10 silver containing dressings. J Wound Care 2003; 12(8): 305-08.
83. Wunderlich U, Orfanos CE. [Treatment of venous ulcera cruris with dry wound dressings. Phase overlapping use of silver impregnated activated charcoal xerodressing]. Hautarzt 1991; 42(7): 446-50.
84. Tebbe B, Orfanos CE. Therapy of leg ulcers and decubitus ulcers with a xero-dressing: modern wound dressings with antibacterial activity. H+G Brand (Special Edition) 1996; 71(9): 11-13.
85. Bornier C, Jeannin C. [Clinical trials with ACTISORB - carried out on 20 cases of complex wounds]. Soins Chir 1989; (99): 39-41.
86. Cassino R, Ricci E, Carousone A. Management of infected wounds: a review of antibiotic and antiseptic treatments (Poster presentation) In: 10th European Wound Management Association conference, 2001; Dublin.
87. Sibbald RG, Browne AC, Coutts P, Queen D. Screening evaluation of an ionized nanocrystalline silver dressing in chronic wound care. Ostomy Wound Manage 2001; 47(10): 38-43.
88. Wright JB, Lam K, Olson ME, Burrell RE. Is antimicrobial efficacy sufficient? A question concerning the benefits of new dressings. Wounds 2003; 15(5): 133-42.
89. Müller G, Winkler Y, Kramer A. Antibacterial activity and endotoxin-binding capacity of Actisorb Silver 220. J Hosp Infect 2003; 53(3): 211-4.
90. O'Neill MA, Vine GJ, Beezer AE, Bishop AH, Hadgraft J, Labetoulle C, Walker M, Bowler PG. Antimicrobial properties of silver-containing wound dressings: a microcalorimetric study. Int J Pharm 2003; 263(1-2): 61-8.
91. Brennan SS, Leaper DJ. The effect of antiseptics on the healing wound: a study using the rabbit ear chamber. Br J Surg 1985; 72(10): 780-2.
92. Lineaweaver W, Howard R, Soucy D, McMorris S, Freeman J, Crain C, Robertson J, Rumley T. Topical antimicrobial toxicity. Arch Surg 1985; 120(3): 267-70.
93. Cochrane CA, Shearwood C, Walker M, Bowler PG, Knottenbelt DC. The application of a fibroblast gel contraction model to assess the cytotoxicity of topical antimicrobial agents. Wounds 2003; 15(8): 265-71.
94. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg 2001; 88(1): 4-21.
95. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284(5418): 1318-22.
96. Kunisada T, Yamada K, Oda S, Hara O. Investigation on the efficacy of povidone-iodine against antiseptic-resistant species. Dermatology 1997; 195 Suppl 2: 14-8.
97. Carson CF, Cookson BD, Farrelly HD, Riley TV. Susceptibility of methicillin-resistant Staphylococcus aureus to the essential oils of Melaleuca alternifolia. J Antimicrob Chemother 1995; 35: 421-24.
98. Caelli M, Porteous J, Carson CF, Heller R, Riley TV. Tea tree oil as an alternative topical decolonisation agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000; 46: 236-37.
99. Ge YG, MacDonald DL, Holyroyd KJ, Thornsberry C, Wexler H, Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 1999; 46(4): 782-88.
100. Beasley WD, Hirst G. Making a meal of MRSA - the role of biosurgery in hospital acquired infection. J Hosp Infect 2004; 56: 6-9.
101. Duckworth DH, Guilig PA. Bacteriophages: potential treatment for bacterial infections. BioDrugs 2002; 16(1): 57-62.
102. White R, Cooper R, Kingsley A. Wound colonization and infection: the role of topical antimicrobials. Br J Nurs 2001; 10(9): 563-78.